Novavax Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.52%
vs ±14.5% implied · ×0.04
shaded = implied · ▲▼ = realized
Linked news
SentenceWe also have contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M™ adjuvant.
NVAX 10-Kaccession 0001000694-26-000007
SentenceIn March 2025, we received a communication (the "Notice") terminating, with immediate effect, the Canada APA on the basis of us not receiving regulatory approval for our COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre Inc. on or before December 31, 2024, pursuant to the terms of the Canada APA.
NVAX 10-Kaccession 0001000694-26-000007
SentenceWe also have contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M™ adjuvant.
NVAX 10-Kaccession 0001000694-26-000007
SentenceIn August 2022, we and SII entered into an influenza license agreement under which we granted SII licenses to develop, manufacture, and commercialize certain vaccine products including influenza vaccine products and influenza and coronavirus combination vaccine products ("CIC") and are obligated to purchase up to approximately $34 million of certain raw materials under related agreements with SII.
NVAX 10-Kaccession 0001000694-26-000007
SentenceIn May 2024, we and SLS entered into a supply agreement (the "SLS Supply Agreement") under which SLS agreed to supply us with antigen drug substance and finished COVID-19 Vaccine doses.
NVAX 10-Kaccession 0001000694-26-000007
SentenceC o-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co- commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines; and (iii) a non- exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $ 500 million and could receive up to $ 700 million contingent on attainment of development, regulatory and commercialization milestones, representing up to $1.2 billion in total.
SentenceWe had an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the "Canadian government"), for the purchase of doses of COVID-19 Vaccine (as amended, the "Canada APA").
NVAX 10-Kaccession 0001000694-26-000007
SentenceFor example, in December 2024, we entered into an amendment to the Australia APA pursuant to which, among other things, we acknowledged the cancellation by Australia of the delivery of certain doses of our COVID-19 Vaccine scheduled for delivery between the fourth quarter of 2023 and the fourth quarter of 2025 and we agreed to credit approximately $31 million of the advanced payment paid by Australia to us against outstanding invoices and invoices for the future delivery of approximately three million doses of COVID-19 Vaccine without requiring additional cash payments.
NVAX 10-Kaccession 0001000694-26-000007
SentenceWe had an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the "Canadian government"), for the purchase of doses of COVID-19 Vaccine (as amended, the "Canada APA").
NVAX 10-Kaccession 0001000694-26-000007
SentenceAs part of the New Zealand Settlement Agreement, we paid Pharmac a refund of previously received upfront payments of $4.0 million.
NVAX 10-Kaccession 0001000694-26-000007
SentenceWe have an agreement with SII related to its manufacture of R21/Matrix-M™ adjuvant malaria vaccine under which SII purchases our Matrix-M™ adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single- to low-double digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country.
NVAX 10-Kaccession 0001000694-26-000007
SentenceWe agreed to supply SLS with all Matrix-M™ adjuvant needed to manufacture finished COVID-19 Vaccine doses.
NVAX 10-Kaccession 0001000694-26-000007
SentenceThese obligations include $133.9 million related to an APA with the Commonwealth of Australia ("Australia") for the purchase of doses of COVID-19 Vaccine (the "Australia APA"), $225.0 million under our APA with the Vaccine Alliance ("Gavi"), and $73.3 million related to various other countries.
NVAX 10-Kaccession 0001000694-26-000007
Novavax has 5 disclosed suppliers and 10 disclosed customers in SEC filings.
Novavax Inc
10.00
Expected move
Inputs8Q avg ±8.7%·×1.44·rich
straddle ±12.8%
spot 10.08exp Nov 6ATM strike 10ATM straddle 1.51IV 137%